Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
Tsuyoshi Otsuji,1 Yoshimi Nagai,2 Kenichiro Sho,1 Akiko Tsumura,1 Naoko Koike,1 Mei Tsuda,1 Tetsuya Nishimura,1 Kanji Takahashi2 1Department of Ophthalmology, Kansai Medical University, Takii Hospital, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical University, Hirakata Hospital, Osaka, J...
Saved in:
Main Authors: | Otsuji T, Nagai Y, Sho K, Tsumura A, Koike N, Tsuda M, Nishimura T, Takahashi K |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/39faaa2deaa44e92a4d7a740e4fe989e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019) -
Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
by: Otsuji T, et al.
Published: (2016) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
by: Tryfon Rotsos, et al.
Published: (2010) -
Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
by: Fujihara M, et al.
Published: (2012) -
Treatment of age-related macular degeneration: focus on ranibizumab
by: Martin S Spitzer, et al.
Published: (2008)